Eledon Pharmaceuticals (ELDN) Change in Acquisitions & Divestments (2016 - 2026)

Eledon Pharmaceuticals (ELDN) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $49.1 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 37.31% year-over-year to $49.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.3 million (up 87.4% YoY) and the FY2025 annual result came in at $171.9 million, up 100.34% from the prior year.
• Change in Acquisitions & Divestments rose to $49.1 million in Q1 2026, from $48.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $49.1 million in Q1 2026 to a low of $16.4 million in Q2 2024.
• A 4-year average of $33.5 million and a median of $31.9 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments declined 9.29% — and 2025, when it surged 158.3%.
• Tracing ELDN's Change in Acquisitions & Divestments over 4 years: stood at $28.0 million in 2023, then decreased by 9.29% to $25.4 million in 2024, then jumped by 91.98% to $48.8 million in 2025, then increased by 0.65% to $49.1 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $49.1 million (Q1 2026), $48.8 million (Q4 2025), and $45.1 million (Q3 2025), per Business Quant data.